Citizens analyst David Turkaly raised the firm’s price target on Lantheus (LNTH) to $115 from $85 and keeps an Outperform rating on the shares. The company delivered another strong quarter with revenue and EPS comfortably ahead of expectations, driven by broad-based strength across PYLARIFY, Neuraceq, DEFINITY, and strategic partnerships, while management maintained what appears to be conservative 2026 guidance due to the early stage of the year, competitive uncertainty, and an incoming CEO transition, even as multiple meaningful catalysts are expected before 2027, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LNTH:
- Lantheus price target raised to $94 from $82 at Goldman Sachs
- Lantheus reports Q1 EPS $1.46, consensus $1.23
- Lantheus backs FY26 adjusted EPS view $5.00-$5.25, consensus $5.17
- Lantheus Holdings Inc (LNTH) Q1 Earnings Cheat Sheet
- AI Models Stay Constructive on Lantheus as a Transitional Period Approaches